INmune Bio Soars in Q4 2025: Advancing CORDStrom and XPro Platforms with Promising Results
In a pivotal year for INmune Bio, the company has made significant strides in advancing its therapeutic platforms, yielding promising results that have sparked investor interest. The company's latest quarterly earnings call revealed a flurry of activity across its portfolio, with CORDStrom and XPro emerging as key drivers of growth.
At the heart of INmune Bio's progress is CORDStrom, a therapy designed to tackle recessive dystrophic epidermolysis bullosa (RDEB). The company has presented additional patient data that showcases clinically meaningful wound healing, reductions in itch, and improvements in quality of life – all with a favorable safety profile. This progress has positioned CORDStrom for regulatory submissions in both the U.K. and the United States, with a MAA filing in the U.K. slated for summer 2026.
What's more, INmune Bio has achieved batch-to-batch manufacturing consistency, ensuring commercial-grade uniformity. The company has also worked out the clinical mechanism of action (MOA) and potency assays for CORDStrom, a crucial step in securing regulatory approval. This repeatable manufacturing reliability, combined with the worked-out MOA, safety data, and clinical results, has given INmune Bio confidence in CORDStrom's potential to revolutionize RDEB treatment.
But CORDStrom is not just a single asset opportunity; it represents a broader platform with potential applications beyond RDEB. The company believes the underlying biology may support development in additional inflammatory and degenerative conditions, as well as genetically modified applications in oncology and rare disease settings. This expansion of therapeutic scope has sent investors abuzz, recognizing the long-term potential of CORDStrom to drive growth and returns.
INmune Bio's CEO, David Moss, emphasized the company's commitment to delivering CORDStrom to patients with RDEB while laying the groundwork for future platform expansion. Moss highlighted the human element of this condition, sharing stories and images that serve as a constant reminder of why INmune Bio does what it does.
Looking ahead, INmune Bio is poised to tackle key regulatory, clinical, and strategic milestones across its portfolio. With CORDStrom at the forefront, the company has set its sights on executing against critical development targets. While challenges lie ahead, INmune Bio's progress in Q4 2025 leaves investors optimistic about the company's prospects for future growth and success.
